SANTORINI data support PCSK9i combinations for high risk patients High Lp(a) linked to plaque progression over 10 years PERI-DYS study suggests need for greater LLT intensification Latest insights from CLEAR Outcomes Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia YELLOW III supports aggressive lipid lowering to reduce plaque progression

Latest PCSK9 Forum news from ESC 2021

Posted on 2 September 2021 |

Related content

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters